A Trial of a Hospital Policy of Tranexamic Acid Use to Reduce Transfusion in Major Non-cardiac Surgery

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

8,440

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

March 5, 2024

Study Completion Date

October 31, 2024

Conditions
Major Non-cardiac Surgeries
Interventions
DRUG

Tranexamic acid (TXA)

TXA 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).

DRUG

Placebo (0.9 % Saline)

Placebo (0.9 % normal saline) 1 gram bolus (2 grams for patients over 100 kg) intravenously (IV) administered within 10 minutes of the first surgical incision, followed by 1 additional gram given intravenously at 2-4 hours of surgery or prior to skin closure, at the discretion of the anesthesiologist (e.g. IV bolus at 2-4 hours of surgery, at skin closure, or the 1 additional gram given as a continuous infusion throughout the surgical procedure).

Trial Locations (9)

R2H 2A6

St. Boniface Hospital, Winnipeg

R3E 0W2

University of Manitoba- HSC Campus, Winnipeg

R3J 3M7

Grace Hospital, Winnipeg

P3E 5J1

Health Sciences North Research Institute, Greater Sudbury

K7L 2V7

Kingston Health Sciences Centre, Kingston

N6A 5A5

London Health Sciences Centre, London

K1H8L6

Ottawa Hospital Research Institute- Civic and General sites, Ottawa

K1K 0T2

Hôpital Montfort, Ottawa

M3M 0B2

Humber River Hospital, Toronto

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Health Sciences Centre Foundation, Manitoba

OTHER

collaborator

The Ottawa Hospital

OTHER

lead

University of Manitoba

OTHER